Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple antibiotic or immunoglobulin shield blood cancer patients from deadly infections?

NCT ID NCT07202078

Disease control Sponsor: Monash University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two infection-prevention strategies in 900 people with blood cancers like myeloma and leukemia. One group gets an antibiotic (co-trimoxazole) daily, while another receives immunoglobulin infusions every few weeks. The goal is to see which approach better prevents severe infections and improves survival. The trial uses an adaptive design, allowing researchers to add new treatments as they go.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Co-trimoxazole (antibiotic) or intravenous/subcutaneous immunoglobulin
What this could lead to
If successful, this could establish a standard way to prevent life-threatening infections in people with blood cancers, reducing hospital stays and improving quality of life.
What could go wrong
This is an early-to-mid stage trial (Phase 2/3) with 900 participants. The treatments may not reduce infections as hoped, or side effects like allergies could limit their use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * None. Exclusion Criteria: 1. Prior or planned allogeneic haematopoietic stem cell transplantation. 2. Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis). 3. Received immunoglobulin replacement in the preceding three months. 4. Objection to receiving immunoglobulin products. 5. Known history of IgA deficiency with anti-IgA. 6. History of severe allergy to immunoglobulin products. 7. Current active infection requiring systemic antibiotics. 8. Allergy or intolerance of all domain antibiotic options. 9. Pregnant or breastfeeding. 10. Severe renal impairment (estimated or measured creatinine clearance of \< 30 mL/min). 11. Previous splenectomy. 12. Previous participation in this domain. 13. Treating team deems enrolment in the domain is not in the best interest of the patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections leukemia lymphoma neoplasm non-Hodgkin lymphoma plasma cell myeloma plasma cell neoplasm infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia Myeloma Non-Hodgkin&#39;S lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Northern Health

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.